Integer (NYSE:ITGR) Releases FY24 Earnings Guidance

Integer (NYSE:ITGR) updated its FY24 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $5.01-5.43 for the period, compared to the consensus estimate of $5.31. The company issued revenue guidance of 1.74-1.77 billion, compared to the consensus revenue estimate of $1.76 billion. Integer also updated its FY 2024 guidance to 5.010-5.430 EPS.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Benchmark reissued a buy rating and set a $130.00 price target on shares of Integer in a report on Friday. CL King assumed coverage on Integer in a report on Thursday, March 14th. They set a buy rating and a $137.00 price target for the company. KeyCorp boosted their price target on Integer from $123.00 to $139.00 and gave the company an overweight rating in a report on Tuesday, April 9th. Finally, Bank of America raised Integer from a neutral rating to a buy rating and boosted their price target for the company from $105.00 to $135.00 in a report on Monday, April 15th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Integer presently has a consensus rating of Moderate Buy and a consensus price target of $120.50.

Integer Price Performance

Shares of NYSE:ITGR traded down $1.57 during trading on Friday, hitting $109.58. 604,251 shares of the company’s stock were exchanged, compared to its average volume of 492,104. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.32 and a quick ratio of 1.71. Integer has a 52-week low of $69.40 and a 52-week high of $123.99. The business’s 50-day simple moving average is $113.11 and its 200 day simple moving average is $99.78. The company has a market cap of $3.67 billion, a price-to-earnings ratio of 37.92, a PEG ratio of 1.54 and a beta of 1.10.

Integer (NYSE:ITGR) last released its earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.02. Integer had a return on equity of 11.25% and a net margin of 6.01%. The firm had revenue of $414.80 million during the quarter, compared to analysts’ expectations of $412.78 million. During the same quarter last year, the business posted $0.87 earnings per share. The firm’s revenue was up 9.5% on a year-over-year basis. As a group, equities analysts predict that Integer will post 5.31 EPS for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.